Company / Net Income
Janux Therapeutics, Inc. Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$113.6M
FY2025
5-year range
-$113.6M / -$32.7M
FY2021-FY2025
Trend
-64.7%
vs FY2024
Sector context
#112 of 214
Health Care
What the data says
At -$114M, Janux Therapeutics, Inc.'s net income ranks #112 of 214 in the Health Care sector. Declined from -$58M to -$114M over the past 2 years.
Based on SEC 10-K filings.
-$114M in FY2025.
Declined from -$58M to -$114M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#112 of 214 in Health CareTop 52% of 214This company -$113.6M Sector average $443.1M
▼
-125.6% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 64.7% year-over-year.
- Ranks #112 out of 214 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$113.6M | -64.7% |
| FY2024 | -$69.0M | -18.4% |
| FY2023 | -$58.3M | +7.6% |
| FY2022 | -$63.1M | -93.0% |
| FY2021 | -$32.7M | -381.6% |
| FY2020 | -$6.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026